基础医学与临床 ›› 2022, Vol. 42 ›› Issue (1): 173-178.

• 短篇综述 • 上一篇    下一篇

垂体腺瘤免疫微环境及免疫治疗的研究进展

郭晓鹏,幸兵,马文斌   

  1. 中国医学科学院 北京协和医学院 北京协和医院
  • 收稿日期:2021-10-12 修回日期:2021-11-22 出版日期:2022-01-05 发布日期:2022-01-05
  • 通讯作者: 幸兵 E-mail:xingbingemail@aliyun.com
  • 基金资助:
    教育部产学合作协同育人项目

Immune microenvironment and immunotherapy in pituitary adenomas

  • Received:2021-10-12 Revised:2021-11-22 Online:2022-01-05 Published:2022-01-05
  • Contact: 兵 幸 E-mail:xingbingemail@aliyun.com

摘要: 垂体腺瘤是第二常见的原发性中枢神经系统肿瘤,多数可通过手术、药物或放疗治愈。但是,部分垂体腺瘤经过传统治疗后仍反复复发并侵袭性生长,甚至发生远端转移,严重缩短了患者生存期并降低了生活质量。近年来,关于脑肿瘤免疫微环境的研究逐渐兴起,尤其在胶质瘤领域,为免疫治疗提供了潜在有效靶点,为提高患者生存创造了条件。但是,既往研究仅对垂体腺瘤微环境中免疫细胞、免疫分子及细胞因子进行了初步分析,对动物和人垂体腺瘤的免疫治疗研究刚刚起步。

关键词: 垂体腺瘤, 免疫微环境, 免疫治疗

Abstract: Pituitary adenomas (PAs) are the second most common primary central nervous system tumors. Although most PAs can be cured with surgery, medical treatment, or radiotherapy, some PAs recur, invade adjacent structures, or even metastasize to other organs after traditional treatments, reducing patient overall survival and their quality of life. In recent years, studies on the immune microenvironment of brain tumors emerged, especially in the field of glioma, providing potential effective treatment targets for immunotherapy and setting the foundation for improving patient survival. However, previous studies have only conducted preliminary analyses on immune cells, immune molecules, and cytokines in the microenvironment of PAs, and immunotherapy research of PAs in animal models and humans has just started.

Key words: pituitary adenoma, immune microenvironment, immunotherapy

中图分类号: